Adaptive B cell responses in rituximab-treated diffuse large B cell lymphoma patients during complete remission
Rituximab is a chimeric monoclonal antibody directed against the CD20 antigen. Treatment using rituximab in combination with chemotherapy has dramatically improved overall survival rate of diffuse large B cell lymphoma (DLBCL). Since rituximab can deplete both lymphoma B cells and normal B cells, how rituximab-treatment affects normal B cell function in DLBCL patients under remission is unclear. Here, we examined peripheral blood B cell composition and antigen-specific B cell responses in DLBCL patients in remission and observed reductions in the frequencies of total B cell as well as several major B cell subsets, including CD19+IgD+ naive B cells, CD19+IgD−CD27+ memory B cells, and CD19loCD27hi plasmablasts. Moreover, tetanus toxin (TT)-specific B cell proliferation was reduced in DLBCL patients in remission. On the other hand, HA-specific IgG-secreting B cell responses could be stimulated by influenza vaccination in DLBCL patients in remission, demonstrating that the machinery for generating de novo adaptive B cell responses was functional in DLBCL patients in remission. Our results provided insights in normal B cell function in DLBCL patients in remission.
KeywordsB cell Rituximab BLDCL Remission
Conflict of interest
- 1.Horner MJ, Ries LAG, Krapcho M, Eisner MP, Kosary CL, Hankey BF, et al. SEER Cancer Statistics Review, 1975–2006. [Internet]. Statistics (Ber). 2006. Available from: http://seer.cancer.gov/csr/1975_2002/Google Scholar
- 5.Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756–65.CrossRefPubMedGoogle Scholar